In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...
Read More
In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...
Read More
In a nutshell This trial looked at the long-term effectiveness of gefitinib (Iressa) compared to vinorelbine (Navelbine) plus cisplatin (Platinol) for stage II-IIIA EGFR-positive non-small cell lung cancer (NSCLC). The authors found that the use of gefitinib improved disease-free survival (DFS) in these...
Read More
In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...
Read More
In a nutshell This trial is examining the effectiveness and safety of short-course radiation therapy and TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) chemotherapy in rectal cancer. The main outcome to be measured will be the change in treatment response. This study is being conducted in the US. The details Colorectal cancer is one of...
Read More
In a nutshell The study evaluated long-term outcomes of combining hypofractionated intensity-modulated radiation therapy (H-IMRT) with prone-positioning in patients after conservation surgery for breast cancer. The authors found that this combination safely controlled cancer locally without affecting regional lymph nodes. Some background Adjuvant...
Read More
In a nutshell This study investigated the effect of atezolizumab (Tecentriq) with chemotherapy before surgery in non-small cell lung cancer (NSCLC). They found that this treatment before surgery was safe and effective. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC)....
Read More
In a nutshell This study investigated the factors predictive of a permanent stoma (PS; an opening in the body that allows waste to exit) in patients with rectal cancer. Researchers suggested that tumor distance from the anus was associated with PS in these patients. Some background Colorectal cancer is the third most common cancer worldwide. The...
Read MoreIn a nutshell This study aimed to evaluate patients treated for early stage breast cancer in terms of overall survival and recurrence risks. Among patients with early-stage breast cancer; clinical outcomes more than 10 years after diagnosis did not differ between breast-conserving therapy plus radiation or mastectomy plus radiation...
Read MoreIn a nutshell This study compared gefitinib (Iressa) to cisplatin (Platinol)-based chemotherapy for treating patients with EGFR-mutation positive, early stage non-small-cell lung cancer, after surgery. The authors concluded that while treatment with gefitinib improved disease free survival compared to chemotherapy, they were unable to calculate overall...
Read MoreIn a nutshell This study aimed to investigate the influence of the time of starting adjuvant chemotherapy on survival outcomes in different types of breast cancer. This study concluded that more aggressive breast cancers require early adjuvant chemotherapy. Some background Surgery to remove the tumor is a commonly used treatment method for...
Read More
In a nutshell This study aimed to investigate zoledronic acid in combination with chemotherapy as a treatment for HER2-negative breast cancer. This study concluded that the addition of zoledronic acid to chemotherapy has potential benefits for certain breast cancer patients. Some background HER2-negative breast cancer (BC) differs from...
Read More
